The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
New Horizons in Antifungal Therapy
Open accessAbstract
Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics. Some of these studies have resulted in the identification of novel compounds that act against these pathways and also demonstrate potent antifungal activity. However, considerable effort is required to move from pre-clinical compound testing to true clinical trials, a necessary step toward ultimately bringing new drugs to market. The rising incidence of invasive fungal infections mandates continued efforts to identify new strategies for antifungal therapy. Moreover, these life-threatening infections often occur in our most vulnerable patient populations. In addition to finding completely novel antifungal compounds, there is also a renewed effort to redirect existing drugs for use as antifungal agents. Several recent screens have identified potent antifungal activity in compounds previously indicated for other uses in humans. Together, the combined efforts of academic investigators and the pharmaceutical industry is resulting in exciting new possibilities for the treatment of invasive fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Cryptococcosis >1,000,000 [6] 20%–70% [6] Candidiasis >400,000 [7] 10%–75% [8] Aspergillosis >200,000 [9,10] 30%–95% [1,10–12]”
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Histoplasmosis: a Clinical and Laboratory Update
Kauffman, C. A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-06 · Cited by 1,200 · cited 2×
“Blastomycosis ~3000 [4] <2%–68% [1,18,19] Coccidioidomycosis ~20,000 [20] <1%–70% [21] Histoplasmosis ~25,000 [22] 28%–50% [5] Paracoccidioidomycosis ~4000 [23] 5%–27% [23] Penicilliosis >8000 [1] 2%–75% [24,25]”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These drugs are primarily used for the treatment of invasive candidiasis and as an alternative therapy for treatment of aspergillosis [53].”
BackgroundAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Amphotericin primarily kills yeast by simply binding ergosterol
Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117280109 · Cited by 608 · cited 5×
“ergosterol binding, but not pore formation, is the key fungicidal feature of amphotericin B [30,119,120].”
BackgroundInfluentialCalcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Sionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“Candida species have a high prevalence of azole resistance, largely attributed to the cytostatic nature of these drugs [37,38].”
BackgroundThe Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458
Clinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 1×
“albicans in vitro and in an invertebrate model of candidiasis [153,154].”
BackgroundRees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 1×
“Pneumocystis Pneumonia >400,000 [1,13] 20%–80% [13–15] Mucormycosis (zygomycosis) >11,000 [16] 30%–90% [16,17]”
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 1×
“albicans in vitro and in an invertebrate model of candidiasis [153,154].”
BackgroundFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Kraus, P. R., Fox, D. S., Cox, G. M., & Heitman, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03508.x · Cited by 217
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205 · cited 5×
“Sertraline Cryptococcus species * 2–6 μg/mL 4 [74]”
BackgroundResultInfluentialHector, R. F., Zimmer, B. L., & Pappagianis, D. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.4.587 · Cited by 189
Calcineurin Is Essential for Candida albicans Survival in Serum and Virulence
Blankenship, J. R., Wormley, F. L., Boyce, M. K., Schell, W. A., Filler, S. G., Perfect, J. R., & Heitman, J. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.3.422-430.2003 · Cited by 186
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183 · cited 1×
“A clinical study in 2014 revealed faster clearance of fungal burden in the cerebrospinal fluid of patients with HIV-associated cryptococcal meningitis who were treated with sertraline in addition to standard antifungal therapy [116].”
BackgroundSionov, E., Chang, Y. C., Garraffo, H. M., & Kwon-Chung, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00295-09 · Cited by 179
Blastomycosis in immunocompromised patients.
Pappas, P. G., Threlkeld, M. G., Bedsole, G. D., Cleveland, K. O., Gelfand, M. S., & Dismukes, W. E. (1993) · Medicine · doi:10.1097/00005792-199309000-00003 · Cited by 177
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173
Del Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.739-746.2000 · Cited by 169
Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 3×
“albicans, treatment with E1210 inhibits germ tube formation, as well as biofilm formation and adherence to plastics [64].”
BackgroundInfluentialFortwendel, J. R., Juvvadi, P. R., Perfect, B. Z., Rogg, L. E., Perfect, J. R., & Steinbach, W. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00854-09 · Cited by 153
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1856 · Cited by 139
Hsp90 orchestrates stress response signaling governing fungal drug resistance
Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000471 · Cited by 130 · cited 1×
“glabrata and Aspergillus fumigatus [151].”
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Dolan, K., Montgomery, S., Buchheit, B., DiDone, L., Wellington, M., & Krysan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01564-08 · Cited by 112 · cited 3×
“Additionally, structural analogs of these triphenylethylene drugs were found to also have potent activity against several Candida and Cryptococcus species [78,110,111].”
BackgroundIn Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111 · cited 5×
“However, it has potent in vitro activity against Candida species, Cryptococcus neoformans, Aspergillus species and Fusarium solani, including echinocandin-resistant Candida isolates [75–77].”
BackgroundInfluentialLamoth, F., & Alexander, B. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-15 · Cited by 100
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99
Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98 · cited 1×
“E1210 has activity against Candida, Aspergillus, Fusarium and even Scedosporium species in vitro, in the ng/mL range for all strains tested [62,65].”
BackgroundButts, A., DiDone, L., Koselny, K., Baxter, B. K., Chabrier-Rosello, Y., Wellington, M., & Krysan, D. J. (2013) · Eukaryotic Cell · doi:10.1128/ec.00314-12 · Cited by 95 · cited 1×
“neoformans, some of which have been discussed above [78,156,157].”
BackgroundLamoth, F., Juvvadi, P. R., Gehrke, C., & Steinbach, W. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01857-12 · Cited by 88 · cited 3×
“Additionally, calcineurin inhibitors, such as tacrolimus (Prograf/FK506), are already in use as immunosuppressants and have potent antifungal activity [148–150].”
BackgroundInfluentialUnraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84 · cited 1×
“neoformans to identify gene-drug interactions that could be leveraged toward antifungal therapy [161].”
BackgroundCoccidioidomycosis-associated Deaths, United States, 1990–2008
Huang, J. Y., Bristow, B., Shafir, S., & Sorvillo, F. (2012) · Emerging Infectious Diseases · doi:10.3201/eid1811.120752 · Cited by 81
Robbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Antifungal Spectrum, In Vivo Efficacy, and Structure–Activity Relationship of Ilicicolin H
Singh, S. B., Liu, W., Li, X., Chen, T., Shafiee, A., Card, D., Abruzzo, G., Flattery, A., Gill, C., Thompson, J. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300173e · Cited by 63 · cited 2×
“Unfortunately, in some cases, resistance to this drug does occur [67].”
BackgroundLaFleur, M. D., Lucumi, E., Napper, A. D., Diamond, S. L., & Lewis, K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq530 · Cited by 59
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
Uptake of T-2307, a novel arylamidine, in Candida albicans
Nishikawa, H., Yamada, E., Shibata, T., Uchihashi, S., Fan, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq177 · Cited by 46
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Kirkpatrick, W. R., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04228-14 · Cited by 36
A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans
Rabjohns, J. L. A., Park, Y.-D., Dehdashti, J., Sun, W., Henderson, C., Zelazny, A., Metallo, S. J., Zheng, W., & Williamson, P. R. (2014) · SLAS Discovery · doi:10.1177/1087057113496847 · Cited by 33 · cited 1×
“neoformans [158] or to search for compounds that affected the viability of Candida biofilms [159].”
BackgroundHartland, K., Pu, J., Palmer, M., Dandapani, S., Moquist, P. N., Munoz, B., DiDone, L., Schreiber, S. L., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00111 · Cited by 24
Cited by
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Hasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Metadata
- Authors
- Pianalto, K., & Alspaugh, J.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2016-10-02
- Volume
- 2
- Issue
- 4
- Pages
- 26
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W2529676164
- Cited by
- 190
- References
- 47
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.